PATZ1 antibody Polyclonal Antibodies Primary antibodies
- Known as:
- PATZ1 (anti-) Polyclonal Antibodies Primary antibodies
- Catalog number:
- orb100111
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Biorb
- Gene target:
- PATZ1 antibody Polyclonal Antibodies Primary antibodies
Related genes to: PATZ1 antibody Polyclonal Antibodies Primary antibodies
- Gene:
- PATZ1 NIH gene
- Name:
- POZ/BTB and AT hook containing zinc finger 1
- Previous symbol:
- ZNF278
- Synonyms:
- MAZR, dJ400N23, ZBTB19, ZSG, RIAZ, PATZ
- Chromosome:
- 22q12.2
- Locus Type:
- gene with protein product
- Date approved:
- 1999-10-20
- Date modifiied:
- 2016-02-10
Related products to: PATZ1 antibody Polyclonal Antibodies Primary antibodies
Related articles to: PATZ1 antibody Polyclonal Antibodies Primary antibodies
- - Source: PubMed
Publication date: 2026/08/04
Shirakura TakahiroYonezawa HajimeArai YasuhitoHama NatsukoFukuoka KoheiYamazaki AyakoKirishima MariYoshida AkihikoYokoo HideakiShibata TatsuhiroHanaya RyosukeNobusawa Sumihito - To understand the mechanisms underlying the remarkable resistance of Göttingen minipigs to metabolic dysfunction-associated steatotic liver disease (MASLD), a multilevel transcriptomic analysis comparing their liver with those of humans, mice, and MASLD susceptible pig breeds was performed. This analysis revealed 692 genes uniquely differentially expressed in livers of Göttingen minipigs, linked to multiple metabolic and signaling pathways (e.g., AMPK signaling). Among these, 11 transcription factors (TFs), 3 hepatokines (DPP4, ITIH1, and ITIH3), and 6 additional secreted proteins (including PCSK9 and APOM) exhibited particularly strong differential expression and emerged as candidate mediators of MASLD resistance. This finding was further supported by weighted gene coexpression network analysis, which identified a core regulatory network driven by the TFs HMBOX1 and PATZ1, presumably regulating 41% of its differentially expressed genes. Collectively, these results suggest that a distinct transcriptional program involving HMBOX1/PATZ1 and their downstream targets, including secreted factors, contributes to the MASLD-resistant phenotype of Göttingen minipigs and may provide promising targets for the prevention and treatment of fatty liver disease. - Source: PubMed
Publication date: 2026/06/25
Gottmann PascalJonas WenkeRenner SimonePhilippou-Massier JuliaHommel TheresaDahlhoff MaikZeigerer AnjaWolf EckhardVogel HeikeSchürmann Annette - Round cell sarcoma with fusion is an extremely rare sarcoma of soft tissue and bones that comes under fusion sarcoma. Molecular studies, such as next-generation sequencing, are essential for accurate diagnosis, as this tumor presents as conventional round cell sarcoma, often co-expressing myogenic and neurogenic markers, which can prompt an erroneous diagnosis of rhabdomyosarcoma (RMS) or malignant peripheral nerve sheath tumor. Due to the rare incidence and paucity of literature on this tumor, the definite prognostic implications and therapeutic guidelines are lacking. Here, we describe two patients with sarcoma, of which one patient was initially misdiagnosed as synovial sarcoma and RMS on two occasions. These patients underscore the diagnostic challenges and therapeutic uncertainties surrounding fusion sarcomas, emphasizing the need for further large collaborative studies to establish optimal prognostic implications and management strategies for this rare entity. - Source: PubMed
Publication date: 2026/06/17
Pasricha SunilRastogi SameerBansal DivyaDharmashaktu YaminiShamim Shamim ABarwad Adarsh - PATZ1-rearranged sarcomas are diagnostically challenging due to their rather non-specific morphology and immunophenotype. These tumors are characterized by bland, round-to-spindled cells within a fibromyxoid matrix with variable microcysts, fibrous septa, hyalinized vessels, and cellular whorls. PATZ1-rearranged sarcomas are often positive for neural, skeletal muscle, and epithelial markers. Identification of these tumors is further complicated by the cryptic nature of the characteristic EWSR1::PATZ1 fusion, which generally makes fluorescence in situ hybridization analysis unreliable if rearrangement is not detected. As a result, costly and time-intensive molecular assays are often currently necessary for definitive diagnosis. The purpose of this study was to assess immunohistochemistry (IHC) for PATZ1 as a surrogate for detecting the gene fusion. In total, 533 tumors from whole-tissue sections and tissue microarrays were evaluated, including 14 PATZ1-rearranged sarcomas as well as other benign and malignant mesenchymal neoplasms. IHC for PATZ1 was positive in 12/14 (86%) PATZ1-rearranged sarcomas. Of the remaining tumor types, 495 (95%) were negative for PATZ1. Notably, PATZ1 expression was observed in a subset of other tumor types, including myoepithelial carcinoma (2/4; 50%), myoepithelioma (2/15; 13%), rhabdomyosarcoma (RMS) (13/99; 13%), desmoplastic small round cell tumor (1/10; 10%), dermatofibrosarcoma protuberans (1/10; 10%), myxoid liposarcoma (1/16; 6%), schwannoma (1/22; 5%), and malignant peripheral nerve sheath tumor (3/70; 4%). The 13 RMS cases that were positive were classified as embryonal (n = 7), alveolar (n = 5), and RMS, not otherwise specified (n = 1). In conclusion, PATZ1 IHC is moderately sensitive and specific for PATZ1-rearranged sarcomas, and it may be a helpful diagnostic marker for this challenging tumor. Although most tumors with morphologic overlap with PATZ1-rearranged sarcomas are negative for PATZ1 by IHC, expression in a subset of myoepithelial tumors and RMS represents a potential diagnostic pitfall. - Source: PubMed
Publication date: 2026/06/10
Gildenberg Melissa SFolpe Andrew LCharville Gregory WHung Yin PHornick Jason LAnderson William J - PML nuclear bodies are cellular structures known to combat DNA viruses. In this study, how human bocavirus 1 (HBoV1), a respiratory pathogen, evades this defense was investigated. PATZ1, a host protein that constitutively regulates gene activity, is recruited by the viral NS1-70 protein to form concentrated clusters adjacent to PML bodies. These clusters bind to the viral DNA and suppress its ability to make new viral genes. To overcome this, the virus produces another protein, NS2, which disrupts the PATZ1 condensates and removes them from the viral DNA, allowing the virus to resume replication. This NS2-mediated antagonism also relieves PATZ1-dependent repression of certain host genes, facilitating viral DNA replication. Beyond HBoV1, PATZ1 also restricts other nuclear-replicating DNA viruses. Our study reveals an intrinsic antiviral mechanism centered on PATZ1-PML condensates and identifies NS2 as a viral antagonist that reprograms host transcription to promote infection. - Source: PubMed
Publication date: 2026/05/28
Tian ChuchuLiu HaibinWei YinFeng JiangpengYu BaochengZuo LiChen ZhenZhang XueyanHao HaojieXu HuanzhouGuan WuxiangSun Yuning